LLY Latest Press Releases

-- February 19, 2026 --

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Ra, and Others | DelveInsight PRNewswire 5:31 PM

Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz) PRNewswire 12:15 PM

-- February 18, 2026 --

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight PRNewswire 6:45 AM

-- February 17, 2026 --

Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight PRNewswire 5:31 PM

Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company Business Wire 8:00 AM

-- February 16, 2026 --

Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight PRNewswire 5:31 PM

Lilly to participate in TD Cowen's 46th Annual Health Care Conference PRNewswire 10:00 AM

USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company PRNewswire 8:00 AM

Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer PRNewswire 6:45 AM

-- February 11, 2026 --

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight PRNewswire 5:31 PM

-- February 9, 2026 --

Lilly to acquire Orna Therapeutics to advance cell therapies PRNewswire 7:00 AM

-- February 5, 2026 --

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX Business Wire 5:21 PM

ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company's Directors and Officers for Breach of Fiduciary Duties - LLY Business Wire 4:00 PM

-- February 4, 2026 --

Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance PRNewswire 6:45 AM

-- January 30, 2026 --

Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility PRNewswire 11:00 AM

-- January 23, 2026 --

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX PRNewswire 8:31 PM

-- January 22, 2026 --

ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company's Directors and Officers for Breach of Fiduciary Duties - LLY Business Wire 10:00 AM

-- January 21, 2026 --

Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement PRNewswire 10:00 AM

-- January 20, 2026 --

Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer PRNewswire 7:45 AM

-- January 9, 2026 --

Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets Business Wire 12:58 PM

-- January 8, 2026 --

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX PRNewswire 8:57 PM

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight PRNewswire 2:00 PM

-- January 7, 2026 --

Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases PRNewswire 4:18 PM

-- December 18, 2025 --

Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial PRNewswire 6:45 AM

-- December 16, 2025 --

Lilly to participate in J.P. Morgan Healthcare Conference PRNewswire 10:00 AM

-- December 12, 2025 --

Updated data for Lilly's Inluriyo (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio (abemaciclib) in ER+, HER2- advanced breast cancer PRNewswire 11:45 AM

-- December 11, 2025 --

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial PRNewswire 6:45 AM

-- December 9, 2025 --

Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama PRNewswire 3:30 PM

Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition PRNewswire 8:29 AM

Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-nave CLL/SLL PRNewswire 7:30 AM

-- December 8, 2025 --

Lilly declares first-quarter 2026 dividend PRNewswire 2:06 PM

Carolyn Bertozzi returns to Lilly board of directors PRNewswire 10:00 AM

-- December 7, 2025 --

Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib) PRNewswire 4:30 PM

-- December 3, 2025 --

U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor PRNewswire 1:00 PM

-- November 24, 2025 --

Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium PRNewswire 4:30 PM

Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting PRNewswire 12:00 PM

Biotech Valuations Rise as New Clinical Platforms Show Progress Globe Newswire 8:30 AM

-- November 19, 2025 --

Lilly announces plans to open Lilly Gateway Labs site in Philadelphia PRNewswire 6:45 AM

-- November 18, 2025 --

Lilly to participate in Citi's 2025 Global Healthcare Conference PRNewswire 10:00 AM

-- November 17, 2025 --

Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy Business Wire 6:07 PM

-- November 10, 2025 --

Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection' PRNewswire 9:13 AM

-- November 6, 2025 --

Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth PRNewswire 4:06 PM

Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans PRNewswire 1:54 PM

Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight PRNewswire 6:45 AM

-- November 3, 2025 --

Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide PRNewswire 8:30 AM

-- October 30, 2025 --

Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance PRNewswire 6:45 AM

-- October 29, 2025 --

Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States PRNewswire 10:30 AM

LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound PRNewswire 7:00 AM

-- October 28, 2025 --

Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients PRNewswire 2:30 PM

Lilly announces roster of Team USA athletes for the Olympic and Paralympic Games Milano Cortina 2026, pledges to translate U.S. Olympic and Paralympic milestones into meaningful community impact PRNewswire 10:00 AM

-- October 27, 2025 --

Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis PRNewswire 4:05 PM

Lilly declares fourth-quarter 2025 dividend PRNewswire 2:00 PM

Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea PRNewswire 1:00 PM

Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis PRNewswire 6:45 AM

-- October 25, 2025 --

Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM Business Wire 11:41 AM

-- October 24, 2025 --

Lilly to Acquire Adverum Biotechnologies PRNewswire 8:30 AM

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis PRNewswire 6:45 AM

Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial PRNewswire 6:45 AM

-- October 21, 2025 --

Big Pharma Just Put Peptides Back on the Map - Which Players Are Still Under the Radar? AB Digital Inc 3:34 PM

-- October 17, 2025 --

Lilly's Verzenio (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment PRNewswire 8:00 AM

-- October 16, 2025 --

Lilly confirms date and conference call for third-quarter 2025 financial results announcement PRNewswire 10:01 AM

-- October 15, 2025 --

Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes PRNewswire 6:45 AM

-- October 13, 2025 --

Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting PRNewswire 6:45 AM

-- October 7, 2025 --

Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis PRNewswire 6:45 AM

-- September 26, 2025 --

Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem PRNewswire 8:30 AM

-- September 25, 2025 --

Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease PRNewswire 6:39 PM

U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer PRNewswire 2:01 PM

-- September 23, 2025 --

Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas PRNewswire 1:00 PM